Vaccine Info

ACI-24 anti-Abeta Vaccine

Authored by
Staff
Last reviewed
April 26, 2022
Fact checked by
Robert Carlson, MD
Share

ACI-24 anti-Abeta Vaccine Description 2022

ACI-24 anti-amyloid-beta (Abeta) vaccine candidates are designed to generate antibodies specifically targeting misfolded Abeta to prevent accumulation and enhance clearance of amyloid plaques.

ACI-24 anti-Abeta vaccine candidates are expected to produce a broad immune response binding key pathological species such as Abeta oligomers and the highly neurotoxic pyroglutamate Abeta (N3pE-Abeta).

ACI-24 anti-Abeta Vaccine Indication

ACI-24 anti-Abeta vaccine candidates are indicated to slow Alzheimer's progress.

ACI-24 anti-Abeta Vaccine News 2022

February 4, 2022 - AC Immune announced their wholly-owned  ACI-24 an amyloid-beta vaccine program preclinical data show the optimized ACI-24 formulation induced a broad polyclonal anti-Abeta response, including high titers of antibodies targeting pyroGlu-Abeta variants, and was well tolerated in non-human primates and mice.

ACI-24 anti-Abeta Vaccine Clinical Trials

The original formulation of ACI-24 has been evaluated in a Phase 1b/2 and a Phase 2 trial in AD patients, and a Phase 1b trial in individuals with Down Syndrome. 

AC Immune will be initiating clinical testing of the optimized ACI-24 formulation in H1 2022.

Clinical Trials

No clinical trials found